A major Wall Street endorsement from multiple analysts recently sent shares of Seagate Technology (NASDAQ: STX) up over 7% in a single session, pushing the stock to a new 52-week high. While any double-digit price target increase is notable, the market’s decisive reaction points to a much .... |
Good MorningWall Street extended its winning streak as major indexes climbed to new highs on broad strength in technology shares. The S&P 500 rose 0.5%, the Dow Jones Industrial Average gained 0.3% and the Nasdaq Composite jumped 0.9%, all setting fresh records. Small-cap stocks also rallied, pushing the Russell 2000 above its 2021 peak. Driving much of today’s surge was a partnership announcement between NVIDIA and Intel, sending NVIDIA higher after it revealed a $5 billion equity investment in its longtime rival as the two plan to co-develop data-center and PC products. International futures reflected the upbeat mood, with Japan’s Nikkei 225 futures trading near multi-year highs.
Fixed-income markets registered notable moves ahead of the Federal Reserve’s anticipated first rate cut, with long-term Treasury yields slipping and mortgage rates dipping to their lowest level since early October. The average 30-year fixed mortgage rate fell to 6.26%, down from 6.35% last week, according to Freddie Mac. Overseas, the Bank of England held its benchmark rate at 4% amid lingering inflation concerns, while commodities saw mixed action: crude oil futures edged lower below $64 a barrel and gold prices retreated as the dollar strengthened slightly.
In corporate news, Uber Eats announced a partnership with drone operator Flytrex to begin U.S. deliveries by year-end, underscoring the growing role of logistics technology in food services. Automakers also made headlines as Toyota and Hyundai issued recalls on more than 1.1 million vehicles over seat-belt and instrument-panel issues, a development that could ripple through auto-supplier stocks. Meanwhile, U.S. homeowners and buyers of electric vehicles and heat pumps are racing to claim expiring federal tax credits before year’s end, setting up a late-season boost in clean-energy and home-improvement demand. Featured: He started with $2,000. Now he's at $3 million. (Ad) 
| Technology | |
A major Wall Street endorsement from multiple analysts recently sent shares of Seagate Technology (NASDAQ: STX) up over 7% in a single session, pushing the stock to a new 52-week high. While any double-digit price target increase is notable, the market’s decisive reaction points to a much ... Read the Full Story |
| From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
| Technology | |
Artificial intelligence (AI) is an all-consuming investment thesis that will last for years, if not decades. For many investors, that means investing in some of the year’s hottest stocks, such as NVIDIA (NASDAQ: NVDA) or Palantir (NASDAQ: PLTR). However, many investors are attracted to compa... Read the Full Story |
| Technology | |
Shares of D-Wave Quantum Inc. (NYSE: QBTS) rallied by an impressive 94% year-to-date, but a closer look reveals that the firm is in danger of losing momentum. When looking at the 12-month trailing return of an astronomical 1,800%, the company's performance over 2025 so far is not quite as notewort... Read the Full Story |
| From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
| Healthcare | |
Eli Lilly and Company (NYSE: LLY) has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, which is transforming the management of type 2 diabetes and the obesity market.
LLY stock is up 10... Read the Full Story |
| Markets | |
The FOMC cut interest rates, but the media response indicated that the cuts were less than expected. However, the headlines focused on next year’s tepid outlook for only 25 basis points of cuts are missing the forest for all the trees. While next year’s outlook is tepid, the forecast f... Read the Full Story |
| From Our Partners | | Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | | Watch the full investigation and decide for yourself |
| Industrials | |
Bloom Energy (NYSE: BE) received two price target upgrades from two major Wall Street firms in two weeks, citing very similar rationale. This served as a launch signal, igniting two additional booster rockets on a stock already accelerating toward triple-digit territory.
BE stock recently jumpe... Read the Full Story |
| Technology | |
After the start of a rally in August that captured significant investor attention, shares of Intel Corporation (NASDAQ: INTC) have entered a period of consolidation, establishing a new and higher base in the $25 to $26 range. This sideways trading, however, follows a period of positive fundament... Read the Full Story |
| Technology | |
During the first half of September, tech giant Apple (NASDAQ: AAPL) made multiple key product and software announcements. Of course, the most talked about is its latest iPhone lineup on Sept. 9, followed by a deeper reveal of its Apple Intelligence features on Sept. 15.
Over the past several ye... Read the Full Story |
| Technology | |
Oracle (NYSE: ORCL) will soon reach a trillion-dollar valuation, driven by the impact of AI on business operations.
Once a bulky, cumbersome shackle, data has become a treasure trove for businesses, and Oracle is leading the charge to unlock it.
Its fiscal Q1 results prove its leadership posit... Read the Full Story |
| Consumer Staples | |
General Mills' (NYSE: GIS) stock sell-off, warranted or not, has aligned its market with long-term trends and presents a generational opportunity for investors. At mid-September levels, the stock is trading at historically low valuations and yielding nearly 5%, a fascinating figure given the out... Read the Full Story |
| Friday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. | Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Thursday, October 15, 2026 at 6:28 PM.
Gilead Sciences Bull Case -
Gilead Sciences, Inc. recently announced a significant collaboration with Vir Biotechnology to discover and develop three PRO-XTEN dual-masked T-cell engagers targeting solid tumor-associated antigens, a move that strengthens the company's oncology pipeline and diversifies its growth beyond its established HIV and hepatitis franchises.
-
The stock is currently trading at $157.37, having recently hit a new 52-week high of $160.51, indicating strong momentum and investor confidence as the company clears previous technical peaks and attracts attention from momentum investors.
-
Wall Street analysts maintain a consensus rating of Moderate Buy with a target price of $159.33, with recent positive actions including HSBC raising its price objective to $175.00 and Needham & Company LLC reiterating a buy rating with a $170.00 target, reflecting constructive sentiment on the company's earnings outlook.
-
Investors can benefit from a dividend yield of 2.22%, supported by a recent quarterly dividend payment of $0.82 per share, which provides a steady income stream and highlights the company's commitment to shareholder returns despite its growth initiatives.
-
The company demonstrated strong financial performance in its most recent quarterly report, with revenue of $7.80 billion exceeding analyst estimates of $7.40 billion and representing a 10.6% year-over-year increase, while also beating consensus EPS estimates by $0.50.
Gilead Sciences Bear Case -
The company reported a negative net margin of 10.64% and a negative return on equity of 2.11% in its latest quarter, along with a negative P/E ratio of -58.94, indicating that the firm is currently operating at a loss on a net basis and may face challenges in profitability.
-
Insider selling has been consistent, with the CEO, CFO, and other insiders selling a total of 105,000 shares worth approximately $14.94 million in the last 90 days, which may signal a lack of confidence from those with the most knowledge of the company's internal operations.
-
Gilead Sciences, Inc. has a high debt-to-equity ratio of 2.03, suggesting that the company relies heavily on debt financing relative to its equity, which could increase financial risk and interest expenses, particularly if interest rates remain elevated or if revenue growth slows.
-
Despite recent positive news, the stock's elevated position near its 52-week high increases the risk of profit-taking, as investors may sell their shares to lock in gains, potentially leading to a pullback in the stock price.
-
Analyst sentiment is not unanimous, with some firms like Zacks Research cutting their rating from strong-buy to hold and Erste Group Bank maintaining a hold rating, indicating that there are differing views on the company's future performance and valuation.
| | View Today's Stock Pick |
|
| |
|
|
